Home > News > Significance of Complement Activation in Alzheimer’s Disease
Alzheimer's Disease & Dementia
Read Time: 6 mins

Significance of Complement Activation in Alzheimer’s Disease

Published Online: June 4th 2011 US Neurology, 2008;4(2):52-55 DOI: http://doi.org/10.17925/USN.2008.04.02.52
Authors: David A Loeffler
Quick Links:
Article
Article Information
Article:

Complement activation is a major inflammatory process whose primary functions are to assist in removing micro-organisms and cellular debris and processing of immune complexes. The complement system is composed of more than 30 plasma and membrane-associated proteins, accounting for approximately 10% of the globulins in vertebrate serum, which function as an inflammatory cascade. Complement can be activated by many factors, including immune complexes, polysaccharides (including lipopolysaccharide, the major component of the outer membrane of Gram-negative bacteria), and neuropathological structures such as senile plaques, neurofibrillary tangles (NFTs), and Lewy bodies.1–4
When activation of the system occurs, native complement proteins are enzymatically cleaved, generating complement ‘activation proteins’ that function as opsinins, anaphylatoxins, and chemokines (see Table 1). The liver is the main source of the complement proteins in peripheral blood, but these proteins are also produced in other tissues and organs, including the brain.5 In the central nervous system (CNS), complement proteins are synthesized by a variety of cells including neurons, microglia, astrocytes, oligodendrocytes, and endothelial cells.5 Three complement pathways, the classic, alternative, and lectin-mediated cascades, have been identified (see Figure 1). These pathways differ in the mechanisms that activate them, but full activation of any of the pathways produces C5b-9, the ‘membrane attack complex’ (MAC). The MAC penetrates the surface membrane of susceptible cells on which it is deposited, and can result in cell lysis if present in sufficient concentrations;6 conversely, sublytic concentrations of the MAC can be protective on some types of cell.7 Complement activation is normally closely regulated through the actions of endogenous complement inhibitory proteins,8 including CD59, clusterin, vitronectin, C1-inhibitor, complement inhibitor C4b-binding protein, decay-activating factor, and factor H. When these regulatory mechanisms are insufficient, then tissue damage can result. Because complement activation exerts both protective and deleterious effects, it has been referred to as a ‘double-edged sword.’1

Status of Complement Activation in the Alzheimer’s Disease Brain

C1q (the first protein in the classic complement pathway), early complement activation proteins (C4 and C3 activation fragments), and the MAC have been demonstrated by immunocytochemical staining in the Alzheimer’s disease (AD) brain on senile plaques, NFTs, neuropil threads, and dystrophic neurites9–12 (see Figure 2). Increased mRNA levels for native complement proteins are also present.13 Complement activation is thought to be triggered in the AD brain primarily by the interaction of complement proteins with aggregated forms of amyloidbeta (Aβ) and tau protein, the major components in plaques and NFTs, respectively.2,3,12 Soluble, non-fibrillar Aβ may also be capable of activating complement, albeit to less of an extent than fibrillar Aβ.14 Complement activation and plaque formation are mutually promoting mechanisms. Aggregated Aβ efficiently binds C1q, activating the classic complement pathway,2 and this process further enhances Aβ aggregation and fibril formation.15 Whether elevated complement activation in AD may result, in part, from impaired local defense mechanisms is not clear, due to conflicting reports about the status of complement inhibitory proteins in the AD brain.16,17
Complement activation in AD was initially reported to be limited to the classic pathway,9 but alternative pathway activation was later reported as well.18 The significance of complement activation in the development and progression of AD is unclear. Several of the activation proteins generated in this process have been demonstrated to exert neuroprotective effects in vitro, including protecting against excitotoxicity,19 Aβ-induced neurotoxicity,20 and apoptosis,7 as well as facilitating the clearance of Aβ by microglia.21 In contrast, the MAC is toxic to neurons on which it is deposited,6 and also to adjacent neurons via ‘bystander lysis.’22 Activation of complement can also enhance other neurotoxic processes in the AD brain: it increases Aβ aggregation15,23 and potentiates its neurotoxicity,24 and it attracts microglia25 and promotes their secretion of inflammatory cytokines.26 The close association of complement staining, particularly the MAC, with pathological structures in the AD brain suggests that complement activation may contribute to the neurodegenerative process in AD, despite the neuroprotective actions of some complement proteins. Indeed, this process was generally accepted to play a deleterious role in AD until the publication in 2002 of a study by Wyss-Coray, et al.27 An animal model of AD, the transgenic APP mouse, was crossed with mice expressing soluble complement receptor-related protein y (sCrry), a rodent-specific inhibitor of early complement activation. The APP/sCrry mice had a two- to three-fold increase in cortical and hippocampal Aβ deposition, together with a 50% loss of pyramidal neurons in region CA3 of the hippocampus. The authors concluded that complement activation may protect against Aβ- induced neurotoxicity. Some subsequent investigations in animal models of AD have also suggested a neuroprotective role for complement in AD; Maier et al.,28 using C3-deficient APP mice, found a beneficial role for C3 in plaque clearance, and Zhou et al.29 found evidence for both detrimental and protective effects of complement in APPQ-/- (C1q-deficient) mice. However, Pillay et al.30 found that intracranial administration of vaccinia virus complement control protein, which inhibits both the classic and alternative complement pathways, significantly reduced memory deficits in APP mice. The relevance of these findings to AD is unclear, because full activation of complement has not been reported in the APP mouse. One reason for this difference from the AD brain is that mouse C1q binds less efficiently than human C1q to human Aβ, resulting in less activation of mouse complement by the human Aβ present in plaques in the APP mouse.31 Lack of appropriate anti-sera for detecting the mouse MAC may be an additional reason why the MAC has not been detected in these animals. Thus, because the main neurotoxic component of complement activation, the MAC, is apparently lacking in these mice, the balance between complement’s neuroprotective and neurotoxic effects may be different in APP mice than in AD patients.

The Role of Complement Activation in the Development of Mild Cognitive Impairment and/or Early Alzheimer’s Disease

Complement activation in the brain has been examined in ‘high pathology controls’ (non-demented elderly subjects who are found, on post mortem examination, to have extensive AD-type brain pathology) and in subjects with mild cognitive impairment (MCI), a transitional state between the cognitive levels in normal (non-cognitively impaired) aged subjects and those with dementia. Plaque-associated MAC staining was only slightly increased in the frontal gyrus in these individuals and was far less than in AD patients, although total plaque numbers were similar between the two groups.32 Zanjani et al.33 subsequently found that early complement activation (C4d) on plaques in the temporal cortex increased in association with total plaque numbers from very mild to severe clinical AD. The MAC was detected on plaques and NFTs in some very mild cases but consistently only in severe AD. A recent study from the author’s laboratory34 measured plaque-associated complement staining in the inferior temporal cortex from aged normal, MCI, and AD patients. Early-stage (iC3b) and late-stage (C9) complement activation was found in low numbers on plaques in both aged normal individuals and subjects with MCI; total and complement-stained plaque numbers did not differ between these two groups and were 2.5- to three-fold less than in subjects with AD. Plaque complement staining was highly correlated with total plaque counts, and both of these parameters were inversely associated with measures of cognition. The authors performed regression analysis in an effort to determine the extent to which plaque-associated complement activation might contribute to cognitive deficits, but the analysis failed because of the strong correlation (‘multicolinearity’) between total plaque counts and complement-stained plaques. So, although complement activation increases in parallel with plaque counts during clinical progression from normal cognition (in aged subjects) to AD dementia, its role in this cognitive loss remains unclear.

Why A Determination of the Role of Complement Activation in Alzheimer’s Disease Is Important

AD is the most common form of dementia, accounting for 60–80% of all cases. According to the Alzheimer’s Association,35 approximately 5.2 million Americans suffer from this disease and, by 2030, the number of Americans aged 65 and over with AD is expected to be approximately 7.7 million. The drugs currently approved by the US Food and Drug Administration (FDA) for treatment of AD do not slow progression of the underlying neuropathology, although they provide short-term symptomatic relief to some patients. If complement activation does play an important role in the development and/or progression of this disease, reducing this process in the brain could produce a major breakthrough in the treatment of AD. Some complement-inhibiting drugs are already available and others are being developed.36 Selectively inhibiting late-stage activation, which produces the neurotoxic MAC, would seem to be a logical approach for inhibiting complement in AD patients. Eculizumab (Soliris, Alexion Pharmaceuticals),37 a humanized anti-C5 monoclonal antibody that prevents C5 cleavage (and, therefore, formation of the MAC) could be considered for a small clinical trial in patients with mild AD. This drug was recently used successfully in a phase III trial in patients with paroxysmal nocturnal hemoglobinuria.38 The extent to which this drug crosses the blood–brain barrier is unknown; however, permeability of the blood–brain barrier to systemically administered antibodies may not be a problem in AD patients, as suggested by two recent clinical trials in which systemic treatment with intravenous immunoglobulins resulted in improvement in cognitive scores.39,40

Conclusions

• Complement activation is a major inflammatory process that co-localizes with neuropathological structures in the AD brain, and progressively increases as this pathology becomes more extensive. It does not appear to be increased in the brains of individuals with MCI, however.
• Despite extensive investigation, the significance of this process in the development and progression of AD is unclear, because it exerts both neuroprotective and neurotoxic effects in vitro. Studies in animal models of AD have not succeeded in resolving this problem.
• A clinical trial in which a selective inhibitor of late-stage complement activation would be administered to AD patients should be considered. ■

Acknowledgment

Support from the William Beaumont Hospital Research Institute is gratefully acknowledged.

Article Information:

References

  1. van Beek J, Elward K, Gasque P, Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection, Ann N Y Acad Sci, 2003;992:56–71.
  2. Rogers J, Cooper NR,Webster S, et al., Complement activation by β- amyloid in Alzheimer disease, Proc Natl Acad Sci U S A, 1992;89: 10016–20.
  3. Shen Y, Lue L, Yang L, et al., Complement activation by neurofibrillary tangles in Alzheimer’s disease, Neurosci Lett, 2001;305:165–8.
  4. Yamada T, McGeer PL, McGeer EG, Lewy bodies in Parkinson’s disease are recognized by antibodies to complement proteins, Acta Neuropathol, 1992;84:100–104.
  5. Barnum SR, Complement biosynthesis in the central nervous system, Crit Rev Oral Biol Med, 1995;6:132–46.
  6. Shen Y, Halperin JA, Lee CM, Complement-mediated neurotoxicity is regulated by homologous restriction, Brain Res, 1995;671:282–92.
  7. Rus H, Cudrici C, Niculescu F, et al., Complement activation in autoimmune demyelination: dual role in neuroinflammation and neuroprotection, J Neuroimmunol, 2006;180:9–16.
  8. Gasque P, Dean YD, McGreal EP, et al., Complement components of the innate immune system in health and disease in the CNS, Immunopharmacology, 2000;49:171–86.
  9. McGeer PL, Akiyama H, Itagaki S, et al., Activation of the classical complement pathway in brain tissue of Alzheimer patients, Neurosci Lett, 1989;107:341–6.
  10. Veerhuis R, Janssen I, Hack CE, et al., Early complement components in Alzheimer’s disease brains, Acta Neuropathol (Berl), 1996,91: 53–60.
  11. Afagh A, Cummings BJ, Cribbs DH, et al., Localization and cell association of C1q in Alzheimer’s disease brain, Exp Neurol, 1996;138:22–32.
  12. Webster S, Lue L-F, Brachova L, et al., Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer’s disease, Neurobiol Aging, 1997;18:415–21.
  13. Walker DG, McGeer PL, Complement gene expression in human brain: comparison between normal and Alzheimer disease cases, Brain Res Mol Brain Res, 1992;14:109–16.
  14. Bergamaschini L, Canziani S, Bottasso B, et al., Alzheimer’s betaamyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner, Clin Exp Immunol, 1999;115:526–33.
  15. Webster S, Glabe C, Rogers J, Multivalent binding of complement protein C1q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation, Biochem Biophys Res Commun, 1995;217:869–75.
  16. McGeer PL,Walker DG, Akiyama H, et al., Detection of the membrane inhibitor of reactive lysis (CD59) in diseased neurons of Alzheimer brain, Brain Res, 1991;544:315–19.
  17. Yasojima K, McGeer EG, McGeer PL, Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease, Brain Res, 1999;833:297–301.
  18. Strohmeyer R, Shen Y, Rogers J, Detection of complement alternative pathway mRNA and proteins in the Alzheimer’s disease brain, Brain Res Mol Brain Res, 2000;81:7–18.
  19. van Beek J, Nicole O, Ali C, et al., Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death, Neuroreport, 2001;12:289–93.
  20. O’Barr SA, Caguioa J, Gruol D, et al., Neuronal expression of a functional receptor for the C5a complement activation fragment, J Immunol, 2001;166:4154–62.
  21. Webster SD, Galvan MD, Ferran E, Antibody-mediated phagocytosis of the amyloid beta-peptide in microglia is differentially modulated by C1q, J Immunol, 2001;166:7496–7503.
  22. McGeer PL, Kawamata T,Walker DG, et al., Microglia in degenerative neurological disease, Glia, 1993;7:84–92.
  23. Webster S, O’Barr S, Rogers J, et al., Enhanced aggregation and beta structure of amyloid beta peptide after coincubation with C1q, J Neurosci Res, 1994;39:448–56.
  24. Schultz J, Schaller J, McKinley M, et al., Enhanced cytotoxicity of amyloid beta-peptide by a complement dependent mechanism, Neurosci Lett, 1994;175:99–102.
  25. Nolte C, Moller T,Walter T, et al., Complement 5a controls motility of murine microglial cells in vitro via activation of an inhibitory G-protein and the rearrangement of the actin cytoskeleton, Neuroscience, 1996;73:1091–1107.
  26. O’Barr S, Cooper NR, The C5a complement activation peptide increases IL-1beta and IL-6 release from amyloid-beta primed human monocytes: implications for Alzheimer’s disease, J Neuroimmunol, 2000;109:87–94.
  27. Wyss-Coray T, Yan F, Lin AH, et al., Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer’s mice, Proc Natl Acad Sci U S A, 2002;99:10837–42.
  28. Maier M, Peng Y, Jiang L, et al., Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice, J Neurosci, 2008;28:6333–41.
  29. Zhou J, Fonseca MI, Pisalyaput K, et al., Complement C3 and C4 expression in C1q sufficient and deficient mouse models of Alzheimer’s Disease, J Neurochem, 2008 Jul 4 (Epub ahead of print).
  30. Pillay NS, Kellaway LA, Kotwal GJ, Early detection of memory deficits and memory improvement with vaccinia virus complement control protein in an Alzheimer’s disease model, Behav Brain Res, 2008;192:173–7.
  31. Webster SD, Tenner AJ, Poulos TL, et al., The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation, Neurobiol Aging, 1999;20:297–304.
  32. Lue LF, Brachova L, Civin WH, et al., Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer’s disease neurodegeneration, J Neuropathol Exp Neurol, 1996;55:1083–8.
  33. Zanjani H, Finch CE, Kemper C, et al., Complement activation in very early Alzheimer disease, Alzheimer Dis Assoc Disord, 2005;19:55–66.
  34. Loeffler DA, Camp DM, Bennett DA, Plaque complement activation and cognitive loss in Alzheimer’s disease, J Neuroinflammation, 2008;5:9.
  35. Alzheimer’s Association, 2008 Alzheimer’s Disease Facts and Figures. Available at: www.alz.org/national/documents/report_alz factsfigures2008.pdf
  36. Mizuno M, Morgan BP, The possibilities and pitfalls for anticomplement therapies in inflammatory diseases, Curr Drug Targets Inflamm Allergy, 2004;3:87–96.
  37. Rother RP, Rollins SA, Mojcik CF, et al., Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria, Nat Biotechnol, 2007,25: 1256–64.
  38. Brodsky RA, Young NS, Antonioli E, et al, Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria, Blood, 2008;111: 1840–47.
  39. Dodel RC, Du Y, Depboylu C, et al., Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer’s disease, J Neurol Neurosurg Psychiatry, 2004;75:1472–4.
  40. Relkin NR, Szabo P, Adamiak B, et al., 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease, Neurobiol Aging, 2008 Feb 20 (Epub ahead of print).

Further Resources

Share this Article
Related Content In Alzheimer's Disease & Dementia
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72